HSIC

Business Context and Reporting Period

Company: Henry Schein, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: April 1, 2006
Business Overview: Henry Schein is a leading distributor of healthcare products and services to office-based practitioners (dental, medical, veterinary) in North America and Europe. The company operates through two reportable segments: Healthcare Distribution and Technology.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 9.3% year-over-year, driven by 11.7% local currency growth (8.3% internal volume, 3.4% acquisitions), partially offset by a 2.4% foreign currency headwind.
• Discontinued Operations Impact: Total Net Income decreased significantly to $16.3 million from $30.9 million due to a $19.4 million after-tax loss on the sale of the Hospital Supply Business. Excluding discontinued operations, income from continuing operations increased 16.8% to $35.6 million.
• Margin Expansion: Gross margin improved to 29.1% from 28.4%, primarily due to improved margin management in the Healthcare Distribution segment (28.1% vs 27.4%).
• Cash Flow: Net cash used in operating activities increased to $38.0 million (from $18.2 million used), attributed to timing changes in inventory and current assets. Net cash used in investing activities rose to $84.8 million, driven by $72.7 million in business acquisitions.
• Accounting Change: The company adopted FAS 123(R) effective January 1, 2006, using the modified retrospective application method, which reduced prior period EPS by $0.03.

Guidance, Outlook, and Risks

• Recent Transactions:
  • Acquisition: Completed acquisition of NLS Animal Health (veterinary distribution) on March 31, 2006, for approximately $110 million in annual revenue. Results will be reflected starting July 1, 2006.
  • Divestiture: Sold the Hospital Supply Business on April 1, 2006, for $36.5 million, resulting in a $32.3 million pre-tax loss.
• Capital Allocation: The company expects to invest up to $55.0 million in capital projects for the remainder of the fiscal year. A $200 million stock repurchase program remains active with $111.5 million remaining as of April 1, 2006.
• Liquidity: Management believes cash, credit facilities ($300 million revolver), and access to capital markets are sufficient for foreseeable needs. Accounts receivable days sales outstanding improved to 42.6 days.
• Risks: Key risks include industry consolidation, foreign currency fluctuations, dependence on third-party suppliers, regulatory changes, and potential increases in shipping costs. The company faces approximately 40 product liability cases, though management believes these are covered by insurance or indemnification.

Investor Verification Checklist

• Discontinued Operations: Verify the impact of the Hospital Supply Business sale on future comparability and the $13.0 million contingent payment obligation.
• Acquisition Integration: Monitor the integration of NLS Animal Health and the timing of revenue recognition (starting Q2 2006).
• Foreign Currency Exposure: Assess the impact of the 10.0% currency decline in the International segment on future earnings.
• Working Capital Trends: Review the increase in cash used for operating activities ($38.0 million) to ensure it is not indicative of a structural shift in inventory management or receivables collection.
• Debt Structure: Confirm the status of the $240 million convertible debt (due 2034) and the $300 million revolving credit facility availability.